Search

Your search keyword '"Veerasingam, Dave"' showing total 30 results
Start Over Author "Veerasingam, Dave"
30 results on '"Veerasingam, Dave"'

1. Developing technologies to assess vascular ageing: a roadmap from VascAgeNet

Author

Zanelli, Serena, primary, Agnoletti, Davide, additional, Alastruey, Jordi, additional, Allen, John, additional, Bianchini, Elisabetta, additional, Bikia, Vasiliki, additional, Boutouyrie, Pierre, additional, Bruno, Rosa Maria, additional, Climie, Rachel, additional, Djamaleddine, Djeldjli, additional, Gkaliagkousi, Eugenia, additional, Giudici, Alessandro, additional, Gopcevic, Kristina, additional, Grillo, Andrea, additional, Guala, Andrea, additional, Hametner, Bernhard, additional, Joseph, Jayaraj, additional, Karimpour, Parmis, additional, Kodithuwakku, Vimarsha, additional, Kyriacou, Panayiotis A, additional, Lazaridis, Antonios, additional, Lonnebakken, Mai Tone, additional, Martina, Maria Raffaella, additional, Mayer, Christopher Clemens, additional, Nabeel, P M, additional, Navickas, Petras, additional, Nemcsik, Janos, additional, Orter, Stefan, additional, Park, Chloe, additional, Pereira, Telmo, additional, Pucci, Giacomo, additional, Amado Rey, Ana Belen, additional, Salvi, Paolo, additional, Gonçalves Seabra, Ana Carolina, additional, Seeland, Ute, additional, van Sloten, Thomas, additional, Spronck, Bart, additional, Stansby, Gerard, additional, Steens, Indra, additional, Stieglitz, Thomas, additional, Tan, Isabella, additional, Veerasingam, Dave, additional, Wassertheurer, Siegfried, additional, Weber, Thomas, additional, Westerhof, Berend E, additional, and Charlton, Peter H, additional

Published
2024
Full Text
View/download PDF

3. Atrial Fibrillation and Early Vascular Aging: Clinical Implications, Methodology Issues and Open Questions—A Review from the VascAgeNet COST Action

Author

Pucci, Giacomo, primary, Grillo, Andrea, additional, Dalakleidi, Kalliopi V., additional, Fraenkel, Emil, additional, Gkaliagkousi, Eugenia, additional, Golemati, Spyretta, additional, Guala, Andrea, additional, Hametner, Bernhard, additional, Lazaridis, Antonios, additional, Mayer, Christopher C., additional, Mozos, Ioana, additional, Pereira, Telmo, additional, Veerasingam, Dave, additional, Terentes-Printzios, Dimitrios, additional, and Agnoletti, Davide, additional

Published
2024
Full Text
View/download PDF

5. Reimagining the Value of Brachial-Ankle Pulse Wave Velocity as a Biomarker of Cardiovascular Disease Risk—A Call to Action on Behalf of VascAgeNet.

Author

Stone, Keeron, Veerasingam, Dave, Meyer, Michelle L., Heffernan, Kevin S., Higgins, Simon, Maria Bruno, Rosa, Bueno, Celia Alvarez, Döerr, Marcus, Schmidt-Trucksäss, Arno, Terentes-Printzios, Dimitrios, Voicehovska, Jūlija, Climie, Rachel E., Park, Chloe, Pucci, Giacomo, Bahls, Martin, and Stoner, Lee

Abstract

This review critiques the literature supporting clinical assessment and management of cardiovascular disease and cardiovascular disease risk stratification with brachial-ankle pulse wave velocity (baPWV). First, we outline what baPWV actually measures—arterial stiffness of both large central elastic arteries and medium-sized muscular peripheral arteries of the lower limb. Second, we argue that baPWV is not a surrogate for carotid-femoral pulse wave velocity. While both measures are dependent on the properties of the aorta, baPWV is also strongly dependent on the muscular arteries of the lower extremities. Increased lower-extremity arterial stiffness amplifies and hastens wave reflections at the level of the aorta, widens pulse pressure, increases afterload, and reduces coronary perfusion. Third, we used an established evaluation framework to identify the value of baPWV as an independent vascular biomarker. There is sufficient evidence to support (1) proof of concept; (2) prospective validation; (3) incremental value; and (4) clinical utility. However, there is limited or no evidence to support (5) clinical outcomes; (6) cost-effectiveness; (8) methodological consensus; or (9) reference values. Fourth, we address future research requirements. The majority of the evaluation criteria, (1) proof of concept, (2) prospective validation, (3) incremental value, (4) clinical utility and (9) reference values, can be supported using existing cohort datasets, whereas the (5) clinical outcomes and (6) cost-effectiveness criteria require prospective investigation. The (8) methodological consensus criteria will require an expert consensus statement. Finally, we finish this review by providing an example of a future clinical practice model. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular age: a review from VascAgeNet

Author

Charlton, Peter H., primary, Paliakaitė, Birutė, additional, Pilt, Kristjan, additional, Bachler, Martin, additional, Zanelli, Serena, additional, Kulin, Dániel, additional, Allen, John, additional, Hallab, Magid, additional, Bianchini, Elisabetta, additional, Mayer, Christopher C., additional, Terentes-Printzios, Dimitrios, additional, Dittrich, Verena, additional, Hametner, Bernhard, additional, Veerasingam, Dave, additional, Žikić, Dejan, additional, and Marozas, Vaidotas, additional

Published
2022
Full Text
View/download PDF

15. DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial

Author

Ben Ali, Walid, primary, Voisine, Pierre, additional, Olsen, Peter Skov, additional, Jeanmart, Hugues, additional, Noiseux, Nicolas, additional, Goeken, Tracy, additional, Satishchandran, Vilas, additional, Cademartiri, Filippo, additional, Cutter, Garry, additional, Veerasingam, Dave, additional, Brown, Craig, additional, Emmert, Maximilian Y, additional, and Perrault, Louis P, additional

Published
2018
Full Text
View/download PDF

16. DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial

Author

Ben Ali, Walid, Voisine, Pierre, Olsen, Peter Skov, Jeanmart, Hugues, Noiseux, Nicolas, Goeken, Tracy, Satishchandran, Vilas, Cademartiri, Filippo, Cutter, Garry, Veerasingam, Dave, Brown, Craig, Emmert, Maximilian Y, Perrault, Louis P, Ben Ali, Walid, Voisine, Pierre, Olsen, Peter Skov, Jeanmart, Hugues, Noiseux, Nicolas, Goeken, Tracy, Satishchandran, Vilas, Cademartiri, Filippo, Cutter, Garry, Veerasingam, Dave, Brown, Craig, Emmert, Maximilian Y, and Perrault, Louis P

Abstract

Introduction Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients. Methods and analysis This ongoing prospective randomised, double-blinded multicentre trial (NCT02272582/NCT02774824) includes patients undergoing isolated CABG requiring at least two SVGs. It compares the impact of DuraGraft, a novel treatment against VGD versus the (SOC; heparinised saline) using a within-patient randomisation (with one SVG treated with DuraGraft and the other treated with SOC). Besides clinical assessments, patients undergo longitudinal 64-slice or better multidetector CT (MDCT) angiography of paired grafts (within each patient) at 4-6 weeks, 3 months and 12 months. Primary endpoints will be the magnitude of change in mean wall thickness and lumen diameter (stenosis) of paired grafts, at 3 and 12 months, respectively. Besides the evaluation of overall safety, longitudinal assessment of each graft (secondary endpoint) is performed in order to obtain insight into graft behaviour after CABG. Enrolment of 119 patients was successfully completed, and analysis of MDCT angiography follow-up is ongoing with the completed analysis becoming available by end of first quarter of 2018. Ethics and dissemination The regional ethics committees have approved the trial. Results will be submitted for publication. Clinical trial identifier NCT02272582 and NCT02774824.

Published
2018

23. Sternal Talon, a novel repair for sternal dehiscence

Author

Subramaniam, Thavakumar, Keita, Luther, and Veerasingam, Dave

Subjects
body regions, animal structures, surgical procedures, operative, cardiovascular diseases, Case Reports, Sternal Talon, sternal dehiscence, musculoskeletal system
Abstract

Sternal dehiscence is a recognised complication after median sternotomy, occurring in 0.5-5% of cases with or without infection. A 72-year-old man presenting with collapse and ventricular tachycardia was investigated for a possible acute cardiac event 2 years after coronary artery bypass grafting for ischemic heart disease. Work-up chest X-ray showed displacement of all sternal wires, and computed tomography (CT) performed to investigate further showed sternal dehiscence with right ventricle wall herniation through the defect and sternal wire breakdown. A decision was made after discussion with the patient to repair the defect using 3 Sternal Talon devices and 2 sternal wires. The patient made an uncomplicated recovery, and the outpatient clinic review after discharge home showed satisfactory and stable sternal union. We report a case of non-infected sternal dehiscence managed successfully with the Sternal Talon without long-term complications.

Published
2015

28. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular age: A review from VascAgeNet

Author

Charlton, Peter, Paliakaite, Birute, Pilt, Kristjan, Bachler, Martin, Zanelli, Serena, Kulin, Daniel, Allen, John, Hallab, Magid, Bianchini, Elisabetta, Mayer, Christopher, Terentes-Printzios, Dimitrios, Dittrich, Verena, Hametner, Bernhard, Veerasingam, Dave, Zikic, Dejan, and Marozas, Vaidotas

Subjects
pulse arrival time, arteriosclerosis, pulse wave velocity, blood pressure, pulse wave, 3. Good health, arterial stiffness, ageing, pulse transit time, photoplethysmography, sense organs, atherosclerosis, distensibility, signal processing, vascular ageing
Abstract

The photoplethysmogram (PPG) signal is widely measured by clinical and consumer devices, and it is emerging as a potential tool for assessing vascular age. The shape and timing of the PPG pulse wave are both influenced by normal vascular ageing, changes in arterial stiffness and blood pressure, and atherosclerosis. This review summarises research into assessing vascular age from the PPG. Three categories of approaches are described: (i) those which use a single PPG signal (based on pulse wave analysis); (ii) those which use multiple PPG signals (such as pulse transit time measurement); and (iii) those which use PPG and other signals (such as pulse arrival time measurement). Evidence is then presented on the performance, repeatability and reproducibility, and clinical utility of PPG-derived parameters of vascular age. Finally, the review outlines key directions for future research to realise the full potential of photoplethysmography for assessing vascular age.

Catalog

Books, media, physical & digital resources
See catalog results